198 related articles for article (PubMed ID: 31984581)
1. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract][Full Text] [Related]
3. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
[TBL] [Abstract][Full Text] [Related]
4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
5. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
6. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
[TBL] [Abstract][Full Text] [Related]
8. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
10. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between IDH1 mutation and prognosis in supratentorial high-grade astrocytomas].
Xie F; Tang JJ; Wang X; Liu YH; Mao Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 44(2):184-7, 192. PubMed ID: 23745251
[TBL] [Abstract][Full Text] [Related]
12. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
13. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
14. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
[TBL] [Abstract][Full Text] [Related]
15. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.
Jungk C; Scherer M; Mock A; Capper D; Radbruch A; von Deimling A; Bendszus M; Herold-Mende C; Unterberg A
J Neurooncol; 2016 Sep; 129(2):319-28. PubMed ID: 27344556
[TBL] [Abstract][Full Text] [Related]
17. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
19. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
20. Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.
Mäkelä K; Nordfors K; Finne J; Jokilammi A; Paavonen T; Haapasalo H; Korja M; Haapasalo J
BMC Cancer; 2014 Aug; 14():623. PubMed ID: 25164322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
